Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma

Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as h...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Immunother
Autors principals: Fenstermaker, Robert A., Ciesielski, Michael J., Qiu, Jingxin, Yang, Nuo, Frank, Cheryl L., Lee, Kelvin P., Mechtler, Laszlo R., Belal, Ahmed, Ahluwalia, Manmeet S., Hutson, Alan D.
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5069322/
https://ncbi.nlm.nih.gov/pubmed/27576783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1890-x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars